Mumfer Syrup 150Ml

COMPOSITION

Each 5 ml contains Iron (III) hydroxide polymaltose complex equivalent to Elemental Iron 50 mg. In a syrup base. 

INDICATIONS

Adults: Prophylaxis and treatment of iron-deficiency anemias such as hypochromic anemia associated with pregnancy and lactation, chronic or acute blood loss, dietary restriction, metabolic disease and postsurgical convalescence. Children: Prophylaxis and treatment of iron-deficiency anemias with acute or chronic blood loss, nutritional deficiency, metabolic diseases. 

CONTRAINDICATIONS

Hypersensitivity to any of the components or other iron preparations. Anaemia not caused by iron deficiency (e.g., hemolytic anemia, disturbances in erythropoiesis, hypoplasia of the marrow). Iron overload (e.g., hemochromatosis, hemosiderosis). 

WARNINGS AND PRECAUTIONS

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children less than 6 years of age. MUMFER syrup is a highly safe product due to the very high LD 50 of IPC. Yet it is advisable to keep this product out of the reach of children. In case of accidental overdose, call a doctor or poison control center immediately. Iron preparations, including iron [III] hydroxide polymaltose, can cause allergic or anaphylactoid reactions. In case of an allergic reaction, Mumfer syrup should be withdrawn immediately and emergency medical attention sought. Do not exceed the recommended dosage. The treatment of any anaemic condition should be under the advice and supervision of a physician. Occasional gastrointestinal discomfort (such as nausea) may be minimized by consuming the medication with meals. Iron containing medications may occasionally cause constipation or diarrhea. medications may occasionally cause constipation or diarrhea. Caution is recommended in patients with allergies and hepatic and renal insufficiency. Caution should be exercised in alcoholism and patients with inflammatory gastrointestinal disease such as ulcers, colitis, etc. 

ADVERSE REACTIONS

Mumfer syrup is very well tolerated with lesser incidence of adverse events vis-a-vis the conventional iron salts. Commonly reported adverse events include: epigastric pain, metallic taste, nausea or vomiting, abdominal discomfort, constipation, diarrhea, black stools, or temporary staining of the teeth. The non-ionic state of IPC ensures that gastric irritation is not seen with IPC, a feature commonly associated with conventional iron preparations. This leads to better patient compliance, a feature not commonly seen with conventional iron preparations. 

DRUG INTERACTIONS

Since, the iron is complex bound, ionic interactions with foodstuff components (phytin, oxalates, tannin, etc.) and concomitant administration of medicaments (tetracyclines, antacids) are unlikely to occur. IPC does not cause teeth staining. The hemoccult-test (selective for hemoglobin) for the detection of occult blood is not impaired and therefore iron therapy must not be interrupted. IPC, like other iron preparations, may decrease the absorption of many drugs. IPC should not be taken within 2 hours of a dose of any of the following drugs: tetracyclines. fluoroquinolones, chloramphenicol, cimetidine, levodopa, levothyroxine, methyldopa or penicillamine. The antacids adsorb IPC in a reversible manner in the pH range 3 to 8 unlike the ferrous compounds which bind irreversibly. But antacids may decrease the absorption of IPC. Antacids should not be taken within 2 hours of a dose of IPC. No interactions are observed between the steroid hormones and IPC (like ferrous compounds). 

OVERDOSAGE

Comparative studies between oral ferrous sulphate and iron polymaltose in rats established an LD 100 of 350 mg/kg for the salt, whereas neither morbidity nor mortality could be produced in doses exceeding 1,000 mg/kg for the complex. The marginally lower absorption of IPC was offset by a greater degree of gastrointestinal tract tolerance; the wide margin of safety may be of importance in reducing the danger of accidental iron overdose.